Impaired fibrinolysis and risk for cardiovascular disease in the metabolic syndrome and type 2 diabetes (Q36415843)

14 August 2017

1 reference

title

Impaired fibrinolysis and risk for cardiovascular disease in the metabolic syndrome and type 2 diabetes (English)

1 reference

14 August 2017

0 references

1 reference

cardiovascular disease

1 reference

Susanne Trost

1

1 reference

14 August 2017

Richard Pratley

series ordinal

2

1 reference

14 August 2017

Burton Sobel

series ordinal

3

1 reference

14 August 2017

publication date

1 February 2006

1 reference

14 August 2017

published in

Current diabetes report

1 reference

14 August 2017

volume

6

1 reference

14 August 2017

issue

1

1 reference

14 August 2017

page(s)

47-54

1 reference

Glycemic control and heart failure among adult patients with diabetes

14 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007/S11892-006-0052-5

Insulin sensitivity and atherosclerosis. The Insulin Resistance Atherosclerosis Study (IRAS) Investigators.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11892-006-0052-5

Induction of plasminogen activator inhibitor type-1 (PAI-1) by proinsulin and insulin in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11892-006-0052-5

Elaboration of type-1 plasminogen activator inhibitor from adipocytes. A potential pathogenetic link between obesity and cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11892-006-0052-5

Angiotensin II and its metabolites stimulate PAI-1 protein release from human adipocytes in primary culture

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11892-006-0052-5

High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11892-006-0052-5

Increased plasminogen activator inhibitor type 1 in coronary artery atherectomy specimens from type 2 diabetic compared with nondiabetic patients: a potential factor predisposing to thrombosis and its persistence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11892-006-0052-5

Plasminogen activator inhibitor type 1 enhances neointima formation after oxidative vascular injury in atherosclerosis-prone mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11892-006-0052-5

Microarray profiling of isolated abdominal subcutaneous adipocytes from obese vs non-obese Pima Indians: increased expression of inflammation-related genes

21 January 2018

1 reference

12 December 2020

Enhanced expression of PAI-1 in visceral fat: possible contributor to vascular disease in obesity

1 reference

12 December 2020

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

1 reference

12 December 2020

Cardiovascular morbidity and mortality associated with the metabolic syndrome

1 reference

12 December 2020

Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction

1 reference

12 December 2020

Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation

1 reference

12 December 2020

Plasminogen activator inhibitor-1 and its cofactor vitronectin stabilize arterial thrombi after vascular injury in mice

1 reference

12 December 2020

The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes

1 reference

12 December 2020

Role of novel markers of inflammation in patients with stable coronary heart disease

1 reference

12 December 2020

Plasminogen activator inhibitor is elevated in plasma and diminished in platelets in patients with diabetes mellitus.

1 reference

12 December 2020

Adipose tissue secretion of plasminogen activator inhibitor-1 in non-obese and obese individuals

1 reference

12 December 2020

Minireview: The adipocyte--at the crossroads of energy homeostasis, inflammation, and atherosclerosis

1 reference

12 December 2020

Metabolic syndrome and 10-year cardiovascular disease risk in the Hoorn Study

1 reference

12 December 2020

Hyperinsulinaemia as long-term predictor of death and ischaemic heart disease in nondiabetic men: The Malmö Preventive Project

1 reference

12 December 2020

Prevalence of insulin resistance in metabolic disorders: the Bruneck Study.

1 reference

12 December 2020

Obesity and impaired fibrinolysis: role of adipose production of plasminogen activator inhibitor-1

1 reference

12 December 2020

Hyperinsulinemia, hyperglycemia, and impaired hemostasis: the Framingham Offspring Study

1 reference

12 December 2020

Effects of ramipril on plasma fibrinolytic balance in patients with acute anterior myocardial infarction. HEART Study Investigators

1 reference

12 December 2020

Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction

1 reference

12 December 2020

Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction

1 reference

12 December 2020

The dysmetabolic syndrome, insulin resistance and increased cardiovascular (CV) morbidity and mortality in type 2 diabetes: aetiological factors in the development of CV complications

1 reference

12 December 2020

Direct attenuation of plasminogen activator inhibitor type-1 expression in human adipose tissue by thiazolidinediones

1 reference

12 December 2020

Diabetes and cardiovascular risk factors: the Framingham study

1 reference

12 December 2020

Nontraditional risk factors for coronary heart disease incidence among persons with diabetes: the Atherosclerosis Risk in Communities (ARIC) Study

1 reference

12 December 2020

Tissue characteristics of restenosis after percutaneous transluminal coronary angioplasty in diabetic patients

1 reference

12 December 2020

Influence of diabetes on 5-year mortality and morbidity in a randomized trial comparing CABG and PTCA in patients with multivessel disease: the Bypass Angioplasty Revascularization Investigation (BARI)

1 reference

12 December 2020

Impaired fasting glucose concentrations in nondiabetic patients with ischemic heart disease: a marker for a worse prognosis

1 reference

12 December 2020

Effects of troglitazone on blood concentrations of plasminogen activator inhibitor 1 in patients with type 2 diabetes and in lean and obese normal subjects

1 reference

12 December 2020

Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group

1 reference

12 December 2020

Plasminogen-activator inhibitor type 1 and coronary artery disease

1 reference

12 December 2020

Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects. A study of two ethnic groups.

1 reference

12 December 2020

Correlation between blood fibrinolytic activity, plasminogen activator inhibitor level, plasma insulin level, and relative body weight in normal and obese subjects

1 reference

12 December 2020

Amelioration of the inhibition of fibrinolysis in elderly, obese subjects by moderate energy intake restriction

1 reference

12 December 2020

Tumor necrosis factor alpha is a key component in the obesity-linked elevation of plasminogen activator inhibitor 1

1 reference

12 December 2020

Relationship of proinsulin and insulin to cardiovascular risk factors in nondiabetic subjects

1 reference

12 December 2020

Troglitazone Improves Defects in Insulin Action, Insulin Secretion, Ovarian Steroidogenesis, and Fibrinolysis in Women with Polycystic Ovary Syndrome1

1 reference

12 December 2020

Intramural plasminogen activator inhibitor type-1 and coronary atherosclerosis

1 reference

12 December 2020

Hyperinsulinemia as an independent risk factor for ischemic heart disease.

1 reference

12 December 2020

A comparison of the prevalence of the metabolic syndrome using two proposed definitions

1 reference

12 December 2020

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

1 reference

12 December 2020

Changes in Arterial Expression of Fibrinolytic System Proteins in Atherogenesis

1 reference

12 December 2020

Augmentation of synthesis of plasminogen activator inhibitor type-1 in arterial endothelial cells by glucose and its implications for local fibrinolysis

1 reference

12 December 2020

Metabolic syndrome and risk of cardiovascular events after myocardial infarction

1 reference

12 December 2020

Post-transcriptional regulation of expression of plasminogen activator inhibitor type 1 mRNA by insulin and insulin-like growth factor 1

1 reference

12 December 2020

Plasma leptin levels are associated with abnormal fibrinolysis in men and postmenopausal women.

1 reference

12 December 2020

Impact of adipose tissue on plasma plasminogen activator inhibitor-1 in dieting obese women

1 reference

12 December 2020

Obesity is associated with macrophage accumulation in adipose tissue

1 reference

12 December 2020

Factors responsible for impaired fibrinolysis in obese subjects and NIDDM patients

1 reference

12 December 2020

NIDDM and its metabolic control predict coronary heart disease in elderly subjects

1 reference

12 December 2020

Adipose tissue as an endocrine organ

1 reference

12 December 2020

The evolving role of inflammation in obesity and the metabolic syndrome

1 reference

12 December 2020

Nicotine induced changes in gene expression by human coronary artery endothelial cells

1 reference

12 December 2020

The potential influence of insulin and plasminogen activator inhibitor type 1 on the formation of vulnerable atherosclerotic plaques associated with type 2 diabetes.

1 reference

12 December 2020

Effects of metformin on insulin secretion, insulin action, and ovarian steroidogenesis in women with polycystic ovary syndrome

1 reference

12 December 2020

Induction of Hyperinsulinemia Combined With Hyperglycemia and Hypertriglyceridemia Increases Plasminogen Activator Inhibitor 1 in Blood in Normal Human Subjects

1 reference

12 December 2020

Ramipril and the development of diabetes.

1 reference

12 December 2020

Increased plasminogen activator inhibitor-1 and vasculopathy. A reconcilable paradox

1 reference

12 December 2020

Stromal cells are the main plasminogen activator inhibitor-1-producing cells in human fat: evidence of differences between visceral and subcutaneous deposits.

1 reference

12 December 2020

Impaired glucose tolerance: what are the clinical implications?

1 reference

12 December 2020

NCEP-Defined Metabolic Syndrome, Diabetes, and Prevalence of Coronary Heart Disease Among NHANES III Participants Age 50 Years and Older

1 reference

12 December 2020

Obesity, haemostasis and the fibrinolytic system

1 reference

12 December 2020

Production of Plasminogen Activator Inhibitor 1 by Human Adipose Tissue: Possible Link Between Visceral Fat Accumulation and Vascular Disease

1 reference

12 December 2020

Visceral fat as a main determinant of plasminogen activator inhibitor 1 level in women

1 reference

12 December 2020

Subcutaneous abdominal, but not femoral fat expression of plasminogen activator inhibitor-1 (PAI-1) is related to plasma PAI-1 levels and insulin resistance and decreases after weight loss

1 reference

12 December 2020

Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults

1 reference

12 December 2020

Relationship of hepatic and peripheral insulin resistance with plasminogen activator inhibitor-1 in Pima Indians

1 reference

12 December 2020

Plasminogen activator inhibitor type 1 is increased in the arterial wall of type II diabetic subjects

1 reference

12 December 2020

The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men

1 reference

12 December 2020

Hemostatic risk factors and insulin sensitivity, regional body fat distribution, and the metabolic syndrome

1 reference

12 December 2020

Banting lecture 1988. Role of insulin resistance in human disease

1 reference

12 December 2020

Angiotensin II type 1 receptor blockers reduce tissue factor activity and plasminogen activator inhibitor type-1 antigen in hypertensive patients: a randomized, double-blind, placebo-controlled study

1 reference

12 December 2020

The myth of the metabolic syndrome

1 reference

12 December 2020

Is hyperglycemia associated with cardiovascular disease? The Framingham Study

1 reference

12 December 2020

Attenuation of neointimal vascular smooth muscle cellularity in atheroma by plasminogen activator inhibitor type 1 (PAI-1).

1 reference

12 December 2020

Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study

1 reference

12 December 2020

Coronary composition and macrophage infiltration in atherectomy specimens from patients with diabetes mellitus

1 reference

12 December 2020

Attenuation of accumulation of neointimal lipid by pioglitazone in mice genetically deficient in insulin receptor substrate-2 and apolipoprotein E.

1 reference

12 December 2020

Fibrinolysis and atherogenesis in the JCR:LA-cp rat in relation to insulin and triglyceride concentrations in blood

1 reference

12 December 2020

Proinsulin-like molecules and plasminogen activator inhibitor type 1 (PAI-1) activity in diabetic and non-diabetic subjects with and without myocardial infarction

1 reference

12 December 2020

Diabetes and decline in heart disease mortality in US adults.

1 reference

12 December 2020

Relationship of metabolic syndrome and fibrinolytic dysfunction to cardiovascular disease

1 reference

12 December 2020

10.1007/S11892-006-0052-5

Identifiers

DOI

1 reference

14 August 2017

1 reference